Zerone Cellvane builds bridge for entry into China, 'Signs agreement with Chinese biotech company'

Zerone Cellvane has partnered with China's 'Chengdu Tsuruidi Medical Science and Technology Co., Ltd.'

On the 27th, a Memorandum of Understanding (MOU) was signed between the Korean and Chinese companies, aiming to revitalize exchanges in the medical industries of both countries. The two companies will regularly hold medical seminars in both Korea and China to promote medical technologies, as well as expand investments, medical networks, and develop new drugs and medical devices.

Chengdu Tsuruidi Medical Science and Technology Co., Ltd. holds 5 'national invention patents' and 2 international patents (PCT), and conducts important research such as the 'Sichuan Province Science and Technology Plan'.

Zerone Cellvane stated, "With this agreement, we will be able to further develop PDRN-related research globally."

"We have also built a bridge for successful future entry into the Chinese market."

Zerone Cellvane is a pharmaceutical company that uses 'PDRN (polydeoxyribonucleoside)' as an anti-inflammatory and pain-reducing product called 'Cellvane Injection'. The company is also accelerating research and development of 'PDRN (polydeoxyribonucleoside)' for the treatment of periodontitis and lung diseases.

 

Post time: December 27, 2023
Reference information from Naver Website: https://news.mt.co.kr/mtview.php?no=2023122714095178520